A 30,000 Injection Assessment of Xevo™ TQ Absolute XR Mass Spectrometer Quantitative Stability and Uptime for Analysis of Naltrexone for Clinical Research

Significance of the topic

The reliable quantification of low-concentration drug analytes in complex biological matrices is central to clinical pharmacology, therapeutic drug monitoring, and large-scale clinical research. Extended high-throughput operation places exacting demands on LC–MS/MS platforms: long-term sensitivity, chromatographic integrity, low carryover, and minimal maintenance are required to sustain productivity and ensure high-quality data across thousands of injections. This study evaluates these aspects for a modern triple-quadrupole platform under a sustained, realistic clinical-laboratory workload.

Objectives and study overview

The primary goal was to assess the long-term quantitative stability, precision, accuracy, and uptime of the Xevo TQ Absolute XR Mass Spectrometer for measuring naltrexone and its active metabolite 6β-naltrexol in human plasma across a prolonged robustness sequence. The experiment consisted of sequential analysis of samples prepared in 96-well plates to generate a cumulative dataset of 30,720 injections (reported as >30,000 injections), simulating continuous high-throughput clinical laboratory operation over ~55 days and injecting >21 mL total human plasma to the system.

Methodology

Sample preparation and calibration:

• Analytes: naltrexone and 6β-naltrexol; internal standards naltrexone-d3 and 6β-naltrexol-d3.
• Calibration range: 0.2–100 ng/mL; quality controls at 0.2 (LLOQ), 0.6, 40, 80 and 100 ng/mL.
• High-throughput protein precipitation in 96-well plates; each plate analyzed five consecutive times before replacement.
• Acceptance criteria: ±15% for most levels, ±20% at LLOQ; carryover limited to 20% of LLOQ.

LC and MS operating conditions (selected):

• LC system: ACQUITY UPLC; injection volume 5 µL; run time 2.1 min; flow 0.8 mL/min; sample temp 10 °C; column temperature 60 °C; reversed-phase chemistry.
• MS: Xevo TQ Absolute XR with StepWave XR slotted bandpass ion guide; ESI+; capillary voltage 0.6 kV; source temp 150 °C; desolvation gas and cone gas flows noted in the study.
• Data processing: waters_connect with QUAN Review and a review-by-exception workflow (1/x^2 weighting for calibration).

Maintenance routine and practical workflow notes:

• Cone assembly cleaning at the start of each week without breaking vacuum.
• Column replaced as needed due to the accelerated test conditions (60 °C accelerating column wear).

Used instrumentation

The principal instruments and components reported in the study:

• Xevo TQ Absolute XR Triple Quadrupole Mass Spectrometer equipped with the StepWave XR slotted bandpass ion guide.
• ACQUITY UPLC system (Waters).
• Standard consumables and solvents: methanol, 0.1% formic acid aqueous and methanolic mobile phases, ultrapure water.
• Informatics: waters_connect with QUAN Review for automated review-by-exception and quantitation management.

Main results and discussion

Operational uptime and robustness:

• The system completed >30,000 injections across ~55 continuous days with no instrument downtime reported for the mass spectrometer.
• More than 21 mL of human plasma was introduced to the platform during the study.

Quantitative performance:

• Reproducibility at LLOQ (0.2 ng/mL) was excellent: replicate injections (n=6) sampled at early, mid and late stages of the study showed overlaying chromatographic peak area profiles with %RSD < 3.0% at LLOQ.
• Calculated concentrations for LLOQ QC samples for both analytes remained stable: ~99.6–99.8% of LLOQ QC values fell within the ±20% acceptance window, and 99.7% of all QC samples across concentration levels met the predefined acceptance criteria (±15% except LLOQ).
• Precision across QC levels was typically <3.5% and remained below 10% in all but a single isolated QCL datapoint attributed to sample preparation variability rather than instrumental drift.

Chromatography and carryover:

• Short 2.1-minute reversed-phase method supported high throughput while preserving chromatographic performance across the sequence; the study reported acceptable carryover below the predefined limit (≤20% of LLOQ).

Role of StepWave XR ion guide:

• The slotted bandpass design filters unwanted high-mass matrix ions, reducing MS1 quadrupole contamination and limiting sensitivity loss due to quadrupole charging — an effect that contributed to sustained sensitivity and fewer maintenance interruptions over prolonged use.

Data processing efficiency:

• Review-by-exception in waters_connect reduced manual review burden and enabled rapid flagging of outliers, improving throughput for large datasets.

Benefits and practical applications

The demonstrated attributes make this platform appropriate for clinical research and high-throughput bioanalysis workflows where sustained long-term performance is required. Specific benefits include:

• Reduced downtime and maintenance frequency, supporting continuous operation for extended multi-week studies.
• High sensitivity at sub-ng/mL levels enabling reliable terminal-phase pharmacokinetic measurement and low-concentration monitoring.
• Reproducible quantitation and low variability that support confident decision-making in clinical trial and therapeutic monitoring contexts.
• Automated data review capabilities that streamline analyst workload and accelerate turnaround for large sample batches.

Future trends and opportunities

Key areas where the demonstrated findings intersect with ongoing trends in clinical and bioanalytical laboratories:

• Continued development of ion guides and contamination-mitigation technologies to further prolong maintenance intervals and preserve sensitivity under heavy matrix loads.
• Integration of automated, rules-based data review and laboratory informatics to scale up sample throughput while maintaining data quality and compliance.
• Application of similar robustness testing across diverse matrices and compound classes to validate universal high-throughput deployment strategies.
• Potential to adapt short-gradient, high-throughput LC methods combined with resilient MS front-ends for large pharmacokinetic and population studies where throughput, cost-per-sample, and long-run stability are critical.

Conclusion

This robustness assessment indicates that the Xevo TQ Absolute XR platform, featuring the StepWave XR ion guide, can deliver sustained quantitative accuracy, precision, and uptime across a >30,000 injection workload in a complex human plasma matrix. The combination of stable sub-ng/mL sensitivity, low variability, minimal carryover, and automated data-review workflows supports its suitability for demanding clinical research and high-throughput bioanalysis applications.

References

1. Brünen S, Bekier NK, Hiemke C, Korf F, Wiedemann K, Jahn H, Kiefer F. Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. Alcohol Alcohol. 2019 Jan;54(1):51–55. doi:10.1093/alcalc/agy067.
2. Stancil SL, Nolte W, Pearce RE, Staggs VS, Leeder JS. The Impact of Age and Genetics on Naltrexone Biotransformation. Drug Metab Dispos. 2022 Feb;50(2):168–173. doi:10.1124/dmd.121.000646.
3. Shen PT, Liu SC, Huang MC, Liu YL. Development of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Analysis of Plasma Naltrexone and Its Active Metabolite in Patients with AUD. Eur J Mass Spectrom (Chichester). 2025 Oct 3:14690667251384047. doi:10.1177/14690667251384047.